The meta-analysis dedicated to reviewing the influence of sodium–glucose cotransporter-2 inhibitors on plasma adiponectin levels revealed significantly increased plasma adiponectin in type 2 diabetic patients administered tofogliflozin, luseogliflozin, and ipragliflozin, but not dapagliflozin [145]. This evidence concerns the gene ADIPOQ and type 2 diabetes mellitus.